<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34619630</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-0341</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>564</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Virology</Title>
          <ISOAbbreviation>Virology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.</ArticleTitle>
        <Pagination>
          <StartPage>33</StartPage>
          <EndPage>38</EndPage>
          <MedlinePgn>33-38</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2021.09.009</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0042-6822(21)00200-2</ELocationID>
        <Abstract>
          <AbstractText>Endemic seasonal coronaviruses cause morbidity and mortality in a subset of patients, but no specific treatment is available. Molnupiravir is a promising pipeline antiviral drug for treating SARS-CoV-2 infection potentially by targeting RNA-dependent RNA polymerase (RdRp). This study aims to evaluate the potential of repurposing molnupiravir for treating seasonal human coronavirus (HCoV) infections. Molecular docking revealed that the active form of molnupiravir, β-D-N<sup>4</sup>-hydroxycytidine (NHC), has similar binding affinity to RdRp of SARS-CoV-2 and seasonal HCoV-NL63, HCoV-OC43 and HCoV-229E. In cell culture models, treatment of molnupiravir effectively inhibited viral replication and production of infectious viruses of the three seasonal coronaviruses. A time-of-drug-addition experiment indicates the specificity of molnupiravir in inhibiting viral components. Furthermore, combining molnupiravir with the protease inhibitor GC376 resulted in enhanced antiviral activity. Our findings highlight that the great potential of repurposing molnupiravir for treating seasonal coronavirus infected patients.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yining</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Pengfei</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Solanki</LastName>
            <ForeName>Kundan</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, Indore, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Zhongren</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Northwest Minzu University, Lanzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peppelenbosch</LastName>
            <ForeName>Maikel P</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baig</LastName>
            <ForeName>Mirza S</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, Indore, India. Electronic address: msb.iit@iiti.ac.in.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Qiuwei</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands. Electronic address: q.pan@erasmusmc.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Virology</MedlineTA>
        <NlmUniqueID>0110674</NlmUniqueID>
        <ISSNLinking>0042-6822</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000656640">GC376</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013451">Sulfonic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.48</RegistryNumber>
          <NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003139" MajorTopicYN="N">Common Cold</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D028941" MajorTopicYN="N">Coronavirus 229E, Human</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058957" MajorTopicYN="N">Coronavirus NL63, Human</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D028962" MajorTopicYN="N">Coronavirus OC43, Human</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012324" MajorTopicYN="N">RNA-Dependent RNA Polymerase</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013451" MajorTopicYN="N">Sulfonic Acids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Drug repurposing</Keyword>
        <Keyword MajorTopicYN="Y">Molnupiravir</Keyword>
        <Keyword MajorTopicYN="Y">RdRp</Keyword>
        <Keyword MajorTopicYN="Y">Seasonal coronavirus</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34619630</ArticleId>
        <ArticleId IdType="pmc">PMC8486977</ArticleId>
        <ArticleId IdType="doi">10.1016/j.virol.2021.09.009</ArticleId>
        <ArticleId IdType="pii">S0042-6822(21)00200-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Agostini M.L., Pruijssers A.J., Chappell J.D., Gribble J., Lu X., Andres E.L., Bluemling G.R., Lockwood M.A., Sheahan T.P., Sims A.C., Natchus M.G., Saindane M., Kolykhalov A.A., Painter G.R., Baric R.S., Denison M.R. Small-molecule antiviral beta-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 2019;93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Consortium W.H.O.S.T., Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V., Abdool Karim Q., Alejandria M.M., Hernandez Garcia C., Kieny M.P., Malekzadeh R., Murthy S., Reddy K.S., Roses Periago M., Abi Hanna P., Ader F., Al-Bader A.M., Alhasawi A., Allum E., Alotaibi A., Alvarez-Moreno C.A., Appadoo S., Asiri A., Aukrust P., Barratt-Due A., Bellani S., Branca M., Cappel-Porter H.B.C., Cerrato N., Chow T.S., Como N., Eustace J., Garcia P.J., Godbole S., Gotuzzo E., Griskevicius L., Hamra R., Hassan M., Hassany M., Hutton D., Irmansyah I., Jancoriene L., Kirwan J., Kumar S., Lennon P., Lopardo G., Lydon P., Magrini N., Maguire T., Manevska S., Manuel O., McGinty S., Medina M.T., Mesa Rubio M.L., Miranda-Montoya M.C., Nel J., Nunes E.P., Perola M., Portoles A., Rasmin M.R., Raza A., Rees H., Reges P.P.S., Rogers C.A., Salami K., Salvadori M.I., Sinani N., Sterne J.A.C., Stevanovikj M., Tacconelli E., Tikkinen K.A.O., Trelle S., Zaid H., Rottingen J.A., Swaminathan S. Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results. N. Engl. J. Med. 2021;384:497–511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7727327</ArticleId>
            <ArticleId IdType="pubmed">33264556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox R.M., Wolf J.D., Plemper R.K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021;6:11–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daelemans D., Pauwels R., De Clercq E., Pannecouque C. A time-of-drug addition approach to target identification of antiviral compounds. Nat. Protoc. 2011;6:925–933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7086561</ArticleId>
            <ArticleId IdType="pubmed">21637207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer W., Eron J.J., Holman W., Cohen M.S., Fang L., Szewczyk L.J., Sheahan T.P., Baric R., Mollan K.R., Wolfe C.R., Duke E.R., Azizad M.M., Borroto-Esoda K., Wohl D.A., Loftis A.J., Alabanza P., Lipansky F., Painter W.P. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021 doi: 10.1101/2021.06.17.21258639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.06.17.21258639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu L., Ye F., Feng Y., Yu F., Wang Q., Wu Y., Zhao C., Sun H., Huang B., Niu P., Song H., Shi Y., Li X., Tan W., Qi J., Gao G.F. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 2020;11:4417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7474075</ArticleId>
            <ArticleId IdType="pubmed">32887884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hofmann H., Pyrc K., van der Hoek L., Geier M., Berkhout B., Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci. U. S. A. 2005;102:7988–7993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1142358</ArticleId>
            <ArticleId IdType="pubmed">15897467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ianevski A., Giri A.K., Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488–W493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7319457</ArticleId>
            <ArticleId IdType="pubmed">32246720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li P., Ikram A., Peppelenbosch M.P., Ma Z., Pan Q. Systematically mapping clinical features of infections with classical endemic human coronaviruses. Clin. Infect. Dis. 2020;73(3):554–555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7543303</ArticleId>
            <ArticleId IdType="pubmed">32926168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li P., Liu J., Ma Z., Bramer W.M., Peppelenbosch M.P., Pan Q. Estimating global epidemiology of low-pathogenic human coronaviruses in relation to the COVID-19 context. J. Infect. Dis. 2020;222:695–696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7377292</ArticleId>
            <ArticleId IdType="pubmed">32497175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Z., Li P., Ji Y., Ikram A., Pan Q. Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses. Lancet Microbe. 2020;1:e151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7836609</ArticleId>
            <ArticleId IdType="pubmed">33521716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynard O., Nguyen X.N., Alazard-Dany N., Barateau V., Cimarelli A., Volchkov V.E. Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses. 2015;7:6233–6240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4690858</ArticleId>
            <ArticleId IdType="pubmed">26633464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schafer A., Dinnon K.H., 3rd, Stevens L.J., Chappell J.D., Lu X., Hughes T.M., George A.S., Hill C.S., Montgomery S.A., Brown A.J., Bluemling G.R., Natchus M.G., Saindane M., Kolykhalov A.A., Painter G., Harcourt J., Tamin A., Thornburg N.J., Swanstrom R., Denison M.R., Baric R.S. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuyver L.J., Whitaker T., McBrayer T.R., Hernandez-Santiago B.I., Lostia S., Tharnish P.M., Ramesh M., Chu C.K., Jordan R., Shi J., Rachakonda S., Watanabe K.A., Otto M.J., Schinazi R.F. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 2003;47:244–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC149013</ArticleId>
            <ArticleId IdType="pubmed">12499198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G., Shean R.C., Bluemling G.R., Kolykhalov A.A., Greninger A.L., Natchus M.G., Painter G.R., Plemper R.K. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urakova N., Kuznetsova V., Crossman D.K., Sokratian A., Guthrie D.B., Kolykhalov A.A., Lockwood M.A., Natchus M.G., Crowley M.R., Painter G.R., Frolova E.I., Frolov I. beta-d-N (4)-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol. 2018;92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5774879</ArticleId>
            <ArticleId IdType="pubmed">29167335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Hoek L., Pyrc K., Jebbink M.F., Vermeulen-Oost W., Berkhout R.J., Wolthers K.C., Wertheim-van Dillen P.M., Kaandorp J., Spaargaren J., Berkhout B. Identification of a new human coronavirus. Nat. Med. 2004;10:368–373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7095789</ArticleId>
            <ArticleId IdType="pubmed">15034574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veiga A., Martins L.G., Riediger I., Mazetto A., Debur M.D.C., Gregianini T.S. More than just a common cold: endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults. J. Med. Virol. 2021;93:1002–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32720706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A., Gralinski L.E., Johnson C.E., Yao W., Kovarova M., Dinnon K.H., 3rd, Liu H., Madden V.J., Krzystek H.M., De C., White K.K., Gully K., Schafer A., Zaman T., Leist S.R., Grant P.O., Bluemling G.R., Kolykhalov A.A., Natchus M.G., Askin F.B., Painter G., Browne E.P., Jones C.D., Pickles R.J., Baric R.S., Garcia J.V. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
